

Supplemental Table 1: Antibodies used in the AIM assay

Reagent	Clone (Source)	Catalog No	Dilution
CD40 pure- functional grade	HB14 (Miltenyi Biotec)	130-094-133	1.5:100
CCR7 - BV711	G043H7 (Biolegend)	353228	1:200
Fixable Live/Dead Blue	(Thermo)	L23105	1:1000
Human FC Block	(BD)	564220	1:20
CD3 - BUV395	UCHT1 (BD)	563546	1:1000
CD8 - BUV805	SK1 (BD)	612889	1:1000
CD16 - BV510	3G8 (Biolegend)	302048	1:1000
CD14 - BV510	63D3 (Biolegend)	367124	1:1000
CD20 - BV510	2H7 (Biolegend)	302340	1:1000
CD45RA - BV570	HI100 (Biolegend)	304132	1:1000
CD4 - cFluor b548	SK3 (Cytex)	R7-20043	1:500
PD-1 - BV785	EH12.2H7 (Biolegend)	329930	1:200
CD69 - FITC	FN50 (Biolegend)	310904	1:200
CD40L - PE-Dazzle594	24-31 (Biolegend)	310840	1:200
CD137 - BUV737	4b4-1 (BD)	741861	1:100
OX40 - APC	Ber-Act35 (Biolegend)	350008	1:100
Brilliant Staining Buffer Plus	(BD)	566385	1:10

Supplement Table 2: Number of subjects with unsolicited adverse events with onset during 28 days after vaccination in the safety analysis population

	COVIVAC		VAXZEVRIA (N = 125) n (%) (95% CI*)
	3 µg (N = 124) n (%) (95% CI*)	6 µg (N = 125) n (%) (95% CI*)	
Number of subjects with:			
One or more adverse events	n= 124	n= 125	n= 125
	36 (29.0%) (21.2-37.9)	29 (23.2%) (16.1-31.6)	39 (31.2%) (23.2-40.1)
Vaccine-related adverse events	n= 124	n= 125	n= 125
	0 (0%) (0.0-2.9)	0 (0%) (0.0-2.9)	0 (0%) (0.0-2.9)
Withdrawn due to an adverse event	n= 124	n= 125	n= 125
	0 (0%) (0.0-2.9)	0 (0%) (0.0-2.9)	0 (0%) (0.0-2.9)

Note: Two-sided 95% confidence intervals (CIs) computed via the Clopper-Pearson method.

Supplement Table 3: Summary of geometric mean titer (GMT) of NT₅₀ against SARS-CoV-2 pseudovirus by age group in the full analysis population

NT ₅₀ measure			COVIVAC		VAXZEVRIA (N = 125)
			3 µg (N = 124)	6 µg (N = 125)	
Baseline (D1)	18-59 yr.	GMT (95% CI)	n = 80	n = 79	n = 79
			5.04 (4.96, 5.13)	5.00 (-)	5.23 (4.78, 5.72)
	≥ 60 yr.	GMT (95% CI)	n = 40	n = 41	n = 34
			5.00 (-)	5.14 (4.86, 5.45)	5.12 (4.88, 5.36)
14 days after the second vaccination (D43)	18-59 yr.	GMT (95% CI)	n = 80	n = 78	n = 79
			153.28 (124.22, 189.15)	176.52 (141.45, 220.27)	99.92 (80.80, 123.56)
	≥ 60 yr.	GMT (95% CI)	n = 40	n = 40	n = 35
			183.57 (133.40, 252.61)	257.87 (181.10, 367.18)	79.49 (55.68, 113.46)
6 months after the second vaccination (D197)	18-59 yr.	GMT (95% CI)	n = 78	n = 78	n = 77
			188.05 (100.93, 350.38)	140.99 (76.57, 259.61)	126.74 (77.40, 207.55)
	≥ 60 yr.	GMT (95% CI)	n = 38	n = 37	n = 34
			98.94 (40.18, 243.62)	116.19 (47.80, 282.45)	50.00 (21.18, 118.03)

Note: - NT₅₀ GMTs are analyzed from subjects with seronegative anti-S IgG at baseline.

Supplement Table 4: Percentage of subjects with NT₅₀ titer sero responses against SARS-CoV-2 pseudovirus as defined by a ≥ 4 -fold increase from baseline by age group in the full analysis population

NT ₅₀ measure ≥ 4 -fold (Titer)			COVIVAC		VAXZEVRIA (N = 125)
			3 μ g (N = 124)	6 μ g (N = 125)	
14 days after the second vaccination (D43)	18-59 yr.	n (%) (95% CI)	n = 82	n = 83	n = 82
			73 (89.0%)	77 (92.8%)	70 (85.4%)
			(80.2-94.9)	(84.9-97.3)	(75.8-92.2)
	≥ 60 yr.	n (%) (95% CI)	n = 42	n = 40	n = 40
			41 (97.6%)	38 (95.0%)	30 (75.0%)
			(87.4-99.9)	(83.1-99.4)	(58.8-87.3)
6 months after the second vaccination (D197)	18-59 yr.	n (%) (95% CI)	n = 80	n = 82	n = 80
			44 (55.0%)	39 (47.6%)	44 (55.0%)
			(43.5-66.2)	(36.4-58.9)	(43.5-66.2)
	≥ 60 yr.	n (%) (95% CI)	n = 40	n = 37	n = 37
			17 (42.5%)	17 (45.9%)	13 (35.1%)
			(27.0-59.1)	(29.5-63.1)	(20.2-52.5)

Note: The 95% CIs are computed via the Clopper-Pearson method. The analysis included subjects regardless of anti S IgG status at baseline.

Supplement Table 5: Summary of geometric mean titer ratio (GMT Ratio) of NT₅₀ against SARS-CoV-2 pseudovirus by age group in the full analysis population

NT ₅₀ measure GMT ratio (95% CI)		COVIVAC		
		6 µg / 3 µg	3 µg / VAXZEVRIA	6 µg / VAXZEVRIA
Baseline (D1)	18-59 yr.	0.99 (0.97 , 1.01)	0.96 (0.88 , 1.05)	0.96 (0.88 , 1.04)
	≥ 60 yr.	1.03 (0.97 , 1.09)	0.98 (0.94 , 1.02)	1.01 (0.93 , 1.08)
14 days after the second vaccination (D43)	18-59 yr.	1.15 (0.85 , 1.56)	1.53 (1.14 , 2.06)	1.77 (1.30 , 2.40)
	≥ 60 yr.	1.40 (0.88 , 2.24)	2.31 (1.45 , 3.69)	3.24 (1.98 , 5.32)
6 months after the second vaccination (D197)	18-59 yr.	0.75 (0.32 , 1.78)	1.48 (0.67 , 3.27)	1.11 (0.51 , 2.43)
	≥ 60 yr.	1.17 (0.34 , 4.08)	1.98 (0.58 , 6.77)	2.32 (0.69 , 7.85)

Note: NT₅₀ GMTs are analyzed from subjects with seronegative anti-S IgG at baseline.

Supplement Table 6: GMT of NT₅₀ against vaccine-homologous SARS-CoV-2 pseudovirus (PNA) compared to live virus (LVNA) 14 days after the second vaccination (D43), with GMT ratio contrasting COVIVAC to AZ in the full analysis population

NT₅₀ by PNA			
Statistic	COVIVAC 3	COVIVAC 6	VAXZEVRIA
N	120	118	114
GMT	162.78	200.72	93.14
95% CI	(136.79, 193.71)	(166.15, 242.47)	(77.70, 111.66)
Statistic	COVIVAC 3/VAXZEVRIA	COVIVAC 6/VAXZEVRIA	
GMT ratio	1.75	2.15	
95% CI	(1.36, 2.24)	(1.66, 2.80)	
NT₅₀ by LVNA			
Statistic	COVIVAC 3	COVIVAC 6	VAXZEVRIA
N	120	117	114
GMT	45.84	70.35	29.84
95% CI	(35.82, 58.66)	(55.91, 88.53)	(23.74, 37.52)
Statistic	COVIVAC 3/VAXZEVRIA	COVIVAC 6/VAXZEVRIA	
GMT ratio	1.54	2.36	
95% CI	(1.10, 2.15)	(1.71, 3.26)	

Note: NT₅₀ GMTs are analyzed from subjects with seronegative anti-S IgG at baseline.

Supplement Table 7: Summary of geometric mean concentration (GMC) in BAU/mL of anti-S IgG assessed by ELISA by age group in the full analysis population

Anti-S IgG measure (BAU/mL)			COVIVAC		VAXZEVRIA (N = 125)
			3 µg (N = 124)	6 µg (N = 125)	
Baseline (D1)	18-59 yr.	GMC (95% CI)	n = 80	n = 79	n = 80
			3.15 (-)	3.15 (-)	3.15 (-)
	≥ 60 yr.	GMC (95% CI)	n = 40	n = 41	n = 35
			3.15 (-)	3.15 (-)	3.15 (-)
14 days after the second vaccination (D43)	18-59 yr.	GMC (95% CI)	n = 80	n = 78	n = 79
			139.60 (112.48 , 173.27)	155.46 (123.39 , 195.87)	366.41 (306.59 , 437.91)
	≥ 60 yr.	GMC (95% CI)	n = 40	n = 40	n = 35
			146.65 (104.62 , 205.56)	224.91 (155.86 , 324.57)	312.37 (211.23 , 461.93)
6 months after the second vaccination (D197)	18-59 yr.	GMC (95% CI)	n = 78	n = 78	n = 77
			166.99 (87.31 , 319.39)	124.64 (65.78 , 236.19)	277.29 (164.97 , 466.07)
	≥ 60 yr.	GMC (95% CI)	n = 40	n = 39	n = 34
			78.28 (30.39 , 201.61)	89.87 (35.08 , 230.22)	107.22 (42.89 , 268.03)

Note: GMCs are analyzed from subjects with seronegative anti-S IgG at baseline.

Supplement Table 8: Summary of geometric mean concentration ratio (GMC Ratio) of anti-S IgG assessed by ELISA by age group in the full analysis population

Anti-S IgG GMC ratio (95% CI)		COVIVAC		
		6 µg / 3 µg	3 µg / VAXZEVRIA	6 µg / VAXZEVRIA
Baseline (D1)	18-59 yr.	1.00 (1.00 , 1.00)	1.00 (1.00 , 1.00)	1.00 (1.00 , 1.00)
	≥ 60 yr.	1.00 (1.00 , 1.00)	1.00 (1.00 , 1.00)	1.00 (1.00 , 1.00)
14 days after the second vaccination (D43)	18-59 yr.	1.11 (0.81 , 1.52)	0.38 (0.29 , 0.50)	0.42 (0.32 , 0.57)
	≥ 60 yr.	1.53 (0.94 , 2.51)	0.47 (0.28 , 0.78)	0.72 (0.42 , 1.22)
6 months after the second vaccination (D197)	18-59 yr.	0.75 (0.30 , 1.84)	0.60 (0.26 , 1.37)	0.45 (0.20 , 1.02)
	≥ 60 yr.	1.15 (0.31 , 4.27)	0.73 (0.20 , 2.70)	0.84 (0.23 , 3.07)

Note: Anti-S IgG GMCs ratio are analyzed from subjects with seronegative anti-S IgG at baseline.

Supplement Table 9: Summary of geometric mean fold rise (GMFR) from baseline of anti-S IgG concentration assessed by ELISA by age group in the full analysis population

Anti-S IgG measure			COVIVAC		VAXZEVRIA (N = 125)
			3 µg (N = 124)	6 µg (N = 125)	
14 days after the second vaccination (D43)	18-59 yr.	GMFR from baseline (95% CI)	n = 81	n = 82	n = 83
			45·18 (36·37 , 56·12)	46·55 (37·08 , 58·43)	108·47 (89·94 , 130·83)
	≥ 60 yr.	GMFR from baseline (95% CI)	n = 42	n = 41	n = 41
			45·03 (32·46 , 62·45)	69·32 (48·25 , 99·59)	87·13 (60·32 , 125·84)
6 months after the second vaccination (D197)	18-59 yr.	GMFR from baseline (95% CI)	n = 79	n = 83	n = 81
			54·93 (28·85 , 104·60)	39·87 (21·68 , 73·30)	78·74 (47·13 , 131·54)
	≥ 60 yr.	GMFR from baseline (95% CI)	n = 42	n = 39	n = 40
			22·64 (9·12 , 56·18)	28·52 (11·13 , 73·06)	35·38 (15·15 , 82·63)

Note: Geometric Mean Fold Rise (GMFR) is the geometric mean of the ratios of post-vaccination to the pre-first vaccination at D1 (baseline).